TY - JOUR
T1 - Targeting Toll-like receptors
T2 - Emerging therapeutics for multiple sclerosis management
AU - Gambuzza, M.
AU - Licata, N.
AU - Palella, E.
AU - Celi, D.
AU - Foti Cuzzola, V.
AU - Italiano, D.
AU - Marino, S.
AU - Bramanti, P.
PY - 2011/10/28
Y1 - 2011/10/28
N2 - Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.
AB - Toll-like receptors (TLR) are important innate immune proteins for the identification and clearance of invading pathogen. TLR signal through adaptor proteins, most commonly myeloid differentiation primary response gene 88 (MyD88). Inappropriate response of specific TLR has been implicated in certain autoimmune diseases, such as multiple sclerosis (MS). Activation of TLR2, TLR4, TLR7 and TLR9 plays a role in experimental allergic encephalomyelitis (EAE), a murine model of MS, while TLR3 activation protects from disease. Therefore, TLR-modulation could be an important adjuvant to current treatments. Here, we focus on TLR involved in EAE and MS pathogenesis highlighting specific components targeting TLR that might offer further therapeutic possibilities.
KW - Innovative therapeutics
KW - Multiple sclerosis
KW - Receptor-targeting
KW - Toll-like receptors
UR - http://www.scopus.com/inward/record.url?scp=80054934482&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80054934482&partnerID=8YFLogxK
U2 - 10.1016/j.jneuroim.2011.08.010
DO - 10.1016/j.jneuroim.2011.08.010
M3 - Article
C2 - 21889214
AN - SCOPUS:80054934482
VL - 239
SP - 1
EP - 12
JO - Journal of Neuroimmunology
JF - Journal of Neuroimmunology
SN - 0165-5728
IS - 1-2
ER -